first neurokinin-1 receptor antagonist, is a new antiemetic indicated for highly and moderately emetogenic chemotherapy, in association with 5-HT3 receptor antagonists and corticosteroids.
A 57-year-old woman presented with a metastatic osteosarcoma of the left calcaneum. She received her first cycle of treatment combining: ifosfamide (2.5 g/m 2 , short i.v. on days 1-2 and 14-15), doxorubicin (30 mg/m 2 on days 1-2 and 14-15) and cisplatinum (50 mg/m 2 on days 14-15), monthly. The antiemetic regimen was the following: 125 mg aprepitant given orally 1 h before chemotherapy; 8 mg i.v. ondansetron and 60 mg i.v. methylprednisolone 30 min before chemotherapy.
Two hours after the first infusion of ifosfamide (day 1), the patient presented typical symptoms of ifosfamide-induced encephalopathy, associating marked sleepiness, dizziness, visual and auditive hallucinations. The patient fully recovered after 6 h. Methylene blue infusion was not required, given the short duration of symptoms [1] . She received the planned treatment on day 2, and the pharmacokinetics of ifosfamide and its metabolites was assessed on this occasion ( Table 1 ). The patient experienced the same symptoms.
Since both aprepitant and ifosfamide are substrates of CYP3A4, a pharmacokinetic interaction involving this metabolic pathway was suspected.
Therefore, chemotherapy was administered on days 14-15 without aprepitant and the pharmacokinetics of ifosfamide was assessed again (Table 1) . Other medications remained the same. After aprepitant withdrawal, the patient did not experience any symptoms of acute encephalopathy.
Ifosfamide is a prodrug that requires activation by hepatic cytochrome P450 (CYP), especially the 3A4 sub-type, leading to the 4-hydroxy-ifosfamide (4OH-Ifo) [2] . Ifosfamide is also converted by CYP3A4 to inactive, neurotoxic metabolites: the 2-and 3-dechloroethyl-ifosfamide (2d-Ifo and 3d-Ifo).
Following aprepitant, we observed at hour 2 an increase by 66.7% of 2d-Ifo and 37.3% of 3d-Ifo which may account for the clinical observation. The clearance of ifosfamide was also 1.6-fold higher. We noticed that the whole metabolism was stimulated.
Following aprepitant, the cytotoxic metabolite 4OH-Ifo was 28.1% higher at hour 2, and 27.7% higher at H4. The faster metabolic clearance is probably related to an inductive effect of aprepitant.
Whereas aprepitant is known to inhibit CYP3A4 [3] , it can also cause a transient induction of CYP3A4 [4] . The strong 
